• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Glenmark Pharmaceuticals receives ANDA approval for Ranolazine

expresspharmaJuly 09, 2019

Tag: Glenmark Pharmaceuticals , FDA , Ranolazine

Glenmark Pharmaceuticals has been granted final approval by the United States Food and Drug Administration (US FDA) for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg, a generic version of Ranexa Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences.

According to IQVIATM sales data for the 12 month period ending May 2019, the Ranexa Extended-Release Tablets, 500 mg and 1,000 mg market achieved annual sales of approximately $929.0 million.

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com

Previous:Cellect Biotechnology, Washington University Finalize Accelerated Clinical Trial Agreement

Next:Natural antioxidant helps improve immune-based therapies by modulating T-cells

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Glenmark Pharmaceuticals receives ANDA approval for Ranolazine | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Daunomycin HCL( FDA)

Daunomycin HCL( FDA)
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
Vecuronium (FDA)

Vecuronium (FDA)
Praziquantel (FDA)

Praziquantel (FDA)
Ranolazine dihydrochloride

Ranolazine dihydrochloride
Etoposide( FDA)

Etoposide( FDA)
Bumetanide (FDA)

Bumetanide (FDA)
Simvastatin (FDA)

Simvastatin (FDA)
Mesnaum (FDA)

Mesnaum (FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service